Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy
Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy
About this item
Full title
Author / Creator
Publisher
Boston: Springer US
Journal title
Language
English
Formats
Publication information
Publisher
Boston: Springer US
Subjects
More information
Scope and Contents
Contents
Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), recently received FDA approval for recurrent glioblastoma. Additionally, several VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKIs) have entered trials for recurrent glioma. Phase II studies of bevacizumab for recurrent GBM have reported incidents of ischemic...
Alternative Titles
Full title
Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3168718
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3168718
Other Identifiers
ISSN
0167-594X
E-ISSN
1573-7373
DOI
10.1007/s11060-011-0579-4
